Clinical Trials Logo

Gastric Adenocarcinoma clinical trials

View clinical trials related to Gastric Adenocarcinoma.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05135845 Suspended - Clinical trials for Gastric Adenocarcinoma

Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma

METIMGAST
Start date: March 22, 2022
Phase: Phase 2
Study type: Interventional

Immunotherapy with anti-PD1 antibodies provides encouraging results on a subset of patients. Capmatinib, a MET inhibitor, has shown an imunomodulatory effect and a synergy with spartalizumab a PD-1 inhibitor. The purpose of this phase II trial is to evaluate the efficacy and safety of the combination of capmatinib + spartalizumab in adult patients with advanced oesogastric adenocarcinoma.

NCT ID: NCT04779151 Suspended - Clinical trials for Head and Neck Cancer

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

NIRADO
Start date: April 7, 2021
Phase: Phase 2
Study type: Interventional

Treatment will consist of a PARP inhibitor (niraparib) monotherapy priming period (cycle 0; 21 days); an anti-PD-1 antibody (Dostarlimab ; TSR-042) will then be added from C1D1 every 21 days in combination for the first 4 cycles, and then every 42 days. Disease will be assessed every 2 cycles (6 weeks) from C3D1 by CT-scan (or MRI or bone scan, if relevant). Patients still under treatment after 1 year may have tumor evaluation spaced out every 3 cycles

NCT ID: NCT04111172 Suspended - Clinical trials for Malignant Solid Neoplasm

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

Start date: November 10, 2020
Phase: Phase 2
Study type: Interventional

This phase IIA trial investigates the side effects of Ad5.F35-hGCC-PADRE vaccine and to see how well it works in treating patients with gastrointestinal adenocarcinoma. Ad5.F35-hGCC-PADRE vaccine may help to train the patient's own immune system to identify and kill tumor cells and prevent it from coming back.

NCT ID: NCT04065139 Suspended - Clinical trials for Gastric Adenocarcinoma

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study

PIPAC EstoK 01
Start date: June 11, 2020
Phase: Phase 2
Study type: Interventional

Peritoneal metastasis is a common pattern in advanced gastric cancer leading to a terminal condition in a very short time. Whatever recent progress regarding systemic chemotherapy using multi drugs association median survival is limited to 6 months with altered quality of life (QoL) after 4 months for all patients. We postulated that a new innovative health technology for delivering intraperitoneal pressurized aerosol of chemotherapy (Doxorubicin and Cisplatin) during laparoscopy can transform that situation offering to double the survival with QoL preservation. Interestingly, PIPAC procedure is made to be applied repeatedly, every 4 to 6 weeks. This therapeutic strategy allows to improved Intra Peritoneal (IP) drugs impregnation and maintained Intra-Veinous (IV) chemotherapy meanwhile. The primary objective of this study is to evaluate and compare 24-month progression free-survival in patients with peritoneal carcinomatosis of gastric cancer treated either with IV chemotherapy and Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) or with IV chemotherapy alone, with preservation of quality of life.